Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

Launched by ABBOTT · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • Zidovudine (AZT).
• • All drugs used for the standard treatment of opportunistic infections.
• • Other drugs used for the treatment of other AIDS conditions if they have been started more than 3 months prior to study entry.
• Patients must have:
• • Diagnosis of AIDS.
• • Weight loss of \> 10 percent premorbid body weight.
• • Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma.
• • Require home total parenteral nutrition (TPN) for a period of approximately 3 months.
• • Life expectancy = or \> 90 days.
• Prior Medication:
• Allowed:
• • Zidovudine (AZT).
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• • Life expectancy \< 90 days.
• • Biliary stasis.
• • History of drug abuse.
• Patients with the following are excluded:
• • Life expectancy \< 90 days.
• • Biliary stasis.
• • History of drug abuse.
• Prior Medication:
• Excluded within 3 months of study entry:
• • Immunomodulators.
• • Experimental antiviral DT. History of drug abuse.